2026-10-08 15:58:00 UTC#433672newconfirmednews
Editas Medicine upgraded at Wells Fargo following Australian gene editing trial approval
seeking alphaimportance 0.40trust 0.70Editas Medicine, Inc. +0.50Wells Fargo & Company +0.20Australia +0.40
EDIT stock news
EDIT stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire7 wire items
2026-09-23 12:29:48 UTC#355444newconfirmednews
Guggenheim upgrades Editas Medicine to Buy, sets $5 price target citing EDIT-401 clinical potential
tradingviewimportance 0.40trust 0.70Editas Medicine, Inc. +0.60Guggenheim Partners, LLC +0.60EDIT-401 +0.60
2026-09-08 21:58:55 UTC#283935duplicateconfirmednews
Editas Medicine's EDIT-401 CRISPR therapy for LDL reduction enters Phase I in Australia; 2027 data expected
2026-08-18 12:58:00 UTC#189756newconfirmednews
Ladenburg Thalmann initiates coverage of Editas Medicine with Buy rating
dow_jonesimportance 0.30trust 0.70Editas Medicine, Inc. +0.30Ladenburg Thalmann Financial Services Inc. +0.20
2026-08-10 11:59:42 UTC#152522newconfirmednews
Editas Medicine Q2 adjusted loss of $0.15 beats $0.27 estimate; revenue $11.89M tops $2.80M forecast
2026-08-07 14:33:06 UTC#145606newforecastnews
Editas Medicine (EDIT) Q3 2026 Earnings Preview: Analysts Forecast $0.27 Loss Per Share and $3.43M Revenue
2026-08-05 20:02:01 UTC#132641newconfirmeddata release